Diabetes (Type 2 Diabetes)

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Short Message Service for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Mobile Phone Short Message Service
Sponsors:   Alexandria University;   High Institute of Public Health, Egypt
Recruiting

Women and Risk of Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   University of Oslo;   Norwegian Diabetes Association
Enrolling by invitation

Pendulum D2D Glucose Control for Adults With Type 2 Diabetes

Conditions:   Type2 Diabetes;   Gastrointestinal Symptoms
Intervention:   Dietary Supplement: Pendulum Glucose Control formulation for T2D
Sponsors:   University of Southern California;   Pendulum Therapeutics
Not yet recruiting

Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Diabetes mellitus Type 2 De-escalation treatment (DET)
Sponsors:   Sciema UG;   Innovative Diabetes Treatment Studies LLC.
Recruiting

Evaluating Outcomes for Ethnically Diverse Patients With Type 2 Diabetes Participating in a Diabetes Education Program

Condition:   Type2 Diabetes
Intervention:   Behavioral: DSMES
Sponsor:   Hoag Memorial Hospital Presbyterian
Completed

IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes

Conditions:   Diabetes Mellitus Type 2 in Obese;   Inflammation;   Metabolic Disease;   Glucose Metabolism Disorders (Including Diabetes Mellitus)
Intervention:   Drug: Anakinra Prefilled Syringe
Sponsor:   University Hospital, Basel, Switzerland
Not yet recruiting

The Insulin Response to the Gut Hormone GIP After Near-normalisation of Plasma Glucose in Patients With Type 2 Diabetes

Condition:   Type2 Diabetes
Interventions:   Drug: Insulin;   Drug: Empagliflozin;   Drug: Metformin
Sponsor:   University Hospital, Gentofte, Copenhagen
Recruiting

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Active, not recruiting

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Tirzepatide;   Drug: Dulaglutide
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Tirzepatide;   Drug: Semaglutide
Sponsor:   Eli Lilly and Company
Recruiting

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Tirzepatide
Sponsor:   Eli Lilly and Company
Recruiting

Efficacy of Automated Bolus Calculation in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Device: Automated bolus calculator;   Other: Education
Sponsor:   Hvidovre University Hospital
Completed

A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin

Condition:   Type 2 Diabetes
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Insulin Degludec
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MEDI0382;   Drug: Placebo;   Drug: Dapaglifozin;   Drug: Metformin
Sponsor:   MedImmune LLC
Completed

A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tirzepatide;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Recruiting

Neurotronic Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities

Condition:   Type 2 Diabetes Mellitus With Circulatory Complciation
Intervention:   Device: The Neurotronic arterial ablation catheter
Sponsors:   Neurotronic, Inc.;   Libra Medical
Recruiting

Postprandial Metabolites of Meal Challenge Test in Diabetes State

Conditions:   Type2 Diabetes;   Postprandial Hyperglycemia
Interventions:   Behavioral: Strategies to lower postprandial hyperglycemia in T2D patients;   Behavioral: Control group
Sponsor:   Universiti Putra Malaysia
Enrolling by invitation

Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity

Condition:   Type 2 Diabetes Mellitus in Obese
Interventions:   Other: NDPR diet;   Other: USDA healthy eating diet
Sponsor:   Beth Israel Deaconess Medical Center
Withdrawn

Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: glucokinase activator;   Drug: Placebo
Sponsor:   PegBio Co., Ltd.
Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE (U300)
Sponsor:   Sanofi
Recruiting

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Efpeglenatide SAR439977;   Drug: Dulaglutide;   Drug: Metformin
Sponsor:   Sanofi
Active, not recruiting

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: PB-119 100 μg+ Glucophage®;   Drug: PB-119 150 μg+ Glucophage®;   Drug: PB-119 200 μg+ Glucophage®;   Drug: PB-119 placebo + Glucophage®
Sponsors:   PegBio Co., Ltd.;   Covance
Completed

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: efpeglenatide (SAR439977);   Drug: placebo
Sponsor:   Sanofi
Active, not recruiting

Diabetes Effects on Long-Term Implant Survival and Success

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institute of Dental and Craniofacial Research (NIDCR)
Completed

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Condition:   T2DM (Type 2 Diabetes Mellitus)
Interventions:   Drug: Cohort A: ORMD-0801;   Drug: Placebo oral capsule;   Drug: Cohort B: ORMD-0801
Sponsors:   Oramed, Ltd.;   Integrium
Active, not recruiting

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide
Sponsors:   AstraZeneca;   Quintiles, Inc.
Active, not recruiting

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Completed

Psychological Distress and Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Psychological Distress
Intervention:   Behavioral: Cognitive-Behavioral Intervention
Sponsor:   Azienda Ospedaliera Universitaria Integrata Verona
Suspended

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Type 2 Diabetes.

Conditions:   Dyslipidemia;   Type 2 Diabetes
Interventions:   Drug: AZD8233 subcutaneous injection;   Drug: Placebo
Sponsors:   AstraZeneca;   Parexel
Recruiting

Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting

Pharmacist-Led Study in Controlling Hypoglycemia in Older Adults With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2 With Hypoglycemia
Interventions:   Behavioral: SUGAR Handshake;   Behavioral: Standard hypoglycaemia education
Sponsor:   University of Lincoln
Recruiting

A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin degludec/liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo;   Biological: Insulin;   Drug: Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Active, not recruiting

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Condition:   Type2 Diabetes
Interventions:   Drug: Empagliflozin;   Drug: Dapagliflozin
Sponsor:   Chungbuk National University Hospital
Active, not recruiting

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide;   Drug: Insulin glargine (HOE901);   Drug: Background therapy
Sponsor:   Sanofi
Terminated

Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Procedure: Roux-en-Y gastric bypass surgery;   Behavioral: Low-calorie diet
Sponsors:   Washington University School of Medicine;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting

Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
Sponsor:   Sanofi
Recruiting

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in China

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Insulin degludec
Sponsor:   Novo Nordisk A/S
Not yet recruiting

Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Other: Aerobic Exercise Training
Sponsors:   Baltimore VA Medical Center;   University of Maryland, College Park
Active, not recruiting

Feasibility Trial of the Bios Device for Continuous Glucose Monitoring

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:  
Sponsor:   GraphWear Technologies Inc.
Recruiting

Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes

Conditions:   Motor Activity;   Health Behavior;   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Physical Activity;   Behavioral: Questionnaires
Sponsors:   University of Colorado, Denver;   National Heart, Lung, and Blood Institute (NHLBI)
Completed

The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.

Conditions:   Diabetes Mellitus, Type 2;   Kidney Function Tests
Intervention:   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting

Screening of Liver Fibrosis in Patients With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   NAFLD;   NASH
Intervention:   Diagnostic Test: Blood tests
Sponsor:   Nantes University Hospital
Not yet recruiting

Precision Medicine in Chinese Patients With Young Onset Diabetes

Condition:   Type 2 Diabetes
Interventions:   Other: Biogenetic explanation and endocrinologist intensive managment;   Other: Usual care management
Sponsor:   Chinese University of Hong Kong
Recruiting

Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)

Condition:   Diabetes
Interventions:   Dietary Supplement: Biomebliss;   Drug: Metformin;   Dietary Supplement: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting

Digital Integrated Healthcare Platform in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Device: Digital integrated healthcare platform
Sponsor:   Samsung Medical Center
Recruiting

Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention

Conditions:   Overweight and Obesity;   Diabetes Mellitus, Type 2;   Metabolic Syndrome;   Genetic Predisposition;   Diet Modification
Interventions:   Other: Normo-carbohydrate meal intake;   Other: High-carbohydrate meal intake;   Other: High-fat meal intake;   Other: High-protein meal intake
Sponsors:   Medical University of Bialystok;   Ministry of Science and Higher Education, Poland
Recruiting

The Effect of Lysulin on Glycemic Control and Advanced Glycation

Condition:   Type 2 Diabetes
Intervention:   Dietary Supplement: Lysulin
Sponsor:   Juraj Koska
Recruiting

Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Conditions:   NAFLD;   Diabetes Mellitus, Type 2;   Hypertriglyceridemia;   Fatty Liver, Nonalcoholic
Interventions:   Drug: ISIS 703802;   Drug: Placebo
Sponsors:   Akcea Therapeutics;   Ionis Pharmaceuticals, Inc.
Active, not recruiting

Liraglutide Hospital Discharge Trial

Condition:   Type 2 Diabetes
Interventions:   Drug: Liraglutide + OADs;   Drug: Glargine + OADs
Sponsors:   Emory University;   Novo Nordisk A/S
Recruiting

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

Conditions:   Hypertension;   Diabetes Mellitus, Type 2
Interventions:   Drug: Ertugliflozin;   Drug: Hydrochlorothiazide 12.5mg;   Device: Microneurography;   Other: SKNA recordings;   Other: Static Handgrip;   Other: Post-handgrip forearm vascular occlusion;   Other: Testing of the Arterial Baroreflex Function
Sponsors:   Cedars-Sinai Medical Center;   Merck Sharp & Dohme Corp.
Withdrawn

"Physiological" Insulin Scheme vs Traditional Scheme for Glycemic Control in Non-critical Hospitalized Patients With Diabetes Mellitus 2

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: NPH insulin;   Drug: Glargine and Lispro insulin
Sponsor:   Universidad de Guanajuato
Completed

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin and Glimepiride (Low Dosage);   Drug: Metformin and Vildagliptin (Low Dosage);   Drug: Metformin and Insulin Glargine U100 (Low Dosage);   Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage);   Drug: Metformin and Glimepiride (Regular Dosage);   Drug: Metformin and Vildagliptin (Regular Dosage);   Drug: Metformin and Insulin Glargine U100 (Regular Dosage);   Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage)
Sponsor:   University of Jordan
Completed

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

Central Mechanisms That Regulate Glucose Metabolism in Humans

Condition:   Type 2 Diabetes
Interventions:   Drug: Diazoxide;   Drug: Glyburide;   Device: Vagal Nerve Stimulator
Sponsors:   Albert Einstein College of Medicine;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type II;   Obesity
Interventions:   Drug: MEDI0382;   Drug: Placebo
Sponsor:   MedImmune LLC
Completed

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: JARDIANCE 10mg;   Drug: JARDIANCE 25mg
Sponsor:   Boehringer Ingelheim
Recruiting

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting

A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Hypoglycemia
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Canagliflozin;   Drug: Placebo (canagliflozin);   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Completed

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: PF-06882961
Sponsor:   Pfizer
Not yet recruiting

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Recruiting

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Urosepsis;   Diabetic Ketoacidosis;   Lower Extremity Amputation
Interventions:   Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors;   Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors;   Drug: Other treatment combinations
Sponsors:   Canadian Network for Observational Drug Effect Studies, CNODES;   Drug Safety and Effectiveness Network, Canada;   Canadian Institutes of Health Research (CIHR)
Completed

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Oral semaglutide;   Drug: Sitagliptin;   Drug: Placebo (oral semaglutide);   Drug: Placebo (sitagliptin)
Sponsor:   Novo Nordisk A/S
Recruiting

A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Oral semaglutide;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Recruiting

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin 287;   Drug: Insulin glargine U100
Sponsor:   Novo Nordisk A/S
Completed

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Standard of care
Sponsor:   Novo Nordisk A/S
Recruiting

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin 287;   Drug: Placebo (insulin 287);   Drug: Metformin;   Drug: Dipeptidyl peptidase-4 inhibitors;   Drug: Insulin glargine;   Drug: Placebo (insulin glargine)
Sponsor:   Novo Nordisk A/S
Active, not recruiting

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin 287;   Drug: Insulin Glargine
Sponsor:   Novo Nordisk A/S
Completed

DISCOVER Global Registry

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting

Evaluation of a Closed-loop Insulin Delivery System at Home With Tailored Home Care Services in Poorly Controlled DT2

Condition:   Diabete Type 2
Interventions:   Device: t:slim X2 with Control-IQ;   Other: home healthcare services;   Other: usual care for daily insulin treatment
Sponsors:   Air Liquide Santé International;   International Clinical Trials Association
Recruiting

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
Sponsor:   Novo Nordisk A/S
Active, not recruiting

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: DPP-4 inhibitors
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting

Inpatient Closed Loop Glucose Control With the Gen 2 GlucoSTAT

Conditions:   Type 1 Diabetes;   Type 2 Diabetes Treated With Insulin
Intervention:   Device: GlucoSTAT
Sponsors:   Massachusetts General Hospital;   Beta Bionics, Inc.
Not yet recruiting

Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes

Conditions:   Charcot Arthropathy;   Type 2 Diabetes
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Hamad Medical Corporation;   Weill Cornell Medical College in Qatar
Completed

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Condition:   Male Subjects With Type II Diabetes (T2DM)
Interventions:   Drug: AZD8601+Placebo (SAD);   Drug: AZD8601+Placebo;   Drug: Placebo+Placebo
Sponsors:   AstraZeneca;   Parexel;   Spandauer Damm 130;   14050;   Berlin, Germany
Completed

Diabetes Research on Patient Stratification

Condition:   Type2 Diabetes
Intervention:  
Sponsor:   Lund University
Completed

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

Conditions:   Type 2 Diabetes Mellitus;   Obese;   Overweight
Interventions:   Radiation: Gastric Emptying test;   Other: Mixed Oral Glucose Tolerance test;   Drug: Conjugated bile acids sodium;   Other: Placebo
Sponsors:   Mayo Clinic;   Satiogen Pharmaceuticals, Inc.
Completed

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin.

Condition:   Type 2 Diabetes
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Not yet recruiting

Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsor:   AstraZeneca
Completed

A Trial of 18F-AV-133 Positron Emission Tomography (PET)

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Drug: 18F-AV-133
Sponsor:   Avid Radiopharmaceuticals
Terminated

The Impact of Medicaid Health Homes on Patients With Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Icahn School of Medicine at Mount Sinai;   Patient-Centered Outcomes Research Institute;   New York City Clinical Data Research Network;   Weill Medical College of Cornell University;   The New York Academy of Medicine
Recruiting

Empagliflozin and Sympathetic Nerve Traffic

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Empagliflozin;   Drug: Hydrochlorothiazide 25 mg
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Recruiting

Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PB-119 75ug;   Drug: PB-119 150ug;   Drug: PB-119 200ug;   Drug: placebo
Sponsors:   PegBio Co., Ltd.;   Tigermed Consulting Co., Ltd
Completed

Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population

Condition:   Type 2 Diabetes
Intervention:   Other: Bone biopsies
Sponsor:   Hospices Civils de Lyon
Recruiting

A Task Analysis Study of DECIDE For African American Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Task Analysis Intervention Group
Sponsors:   University of Kansas Medical Center;   Wichita State University;   National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.

Condition:   Diabetes
Intervention:  
Sponsor:   AstraZeneca
Completed

Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Diabetes Mellitus, Type 1
Interventions:   Drug: 3 hours humulin R 100 IU/mL PIT;   Drug: 2 hours humulin R 100 IU/mL PIT
Sponsors:   Sciema UG;   Innovative Diabetes Treatment Studies LLC.
Recruiting

Cynara Scolymus Extract for Treatment of Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Cynara Scolymus
Sponsor:   Stefan Fischli
Not yet recruiting

Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes
Intervention:   Procedure: Doubly labelled water method
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Active, not recruiting

Efficacy and Safety of GP40081 Сompared to NovoMix® 30 FlexPen® in Type 2 Diabetes Mellitus Patients

Conditions:   Diabetes Mellitus, Type 2;   Diabetes Mellitus
Interventions:   Drug: GP40081;   Drug: NovoMix 30
Sponsor:   Geropharm
Not yet recruiting

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: semaglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin Degludec/Insulin Aspart
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

Comparative Effectiveness of Empagliflozin in the US

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: DPP-4 inhibitor
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Conditions:   Type2 Diabetes;   Myocardial Infarction;   Ischemic Stroke;   Cardiovascular Death;   Heart Failure;   All-Cause Mortality
Interventions:   Drug: Sodium-glucose cotransporter 2 (SGLT2) inhibitors;   Drug: Dipeptidyl peptidase-4 (DPP-4) inhibitors
Sponsors:   Canadian Network for Observational Drug Effect Studies, CNODES;   Drug Safety and Effectiveness Network, Canada;   Canadian Institutes of Health Research (CIHR)
Completed

A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Completed

Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19

Condition:   Type 2 Diabetes Mellitus
Interventions:   Other: GLP-2;   Other: GIP;   Other: Placebo
Sponsors:   University of Copenhagen;   Hvidovre University Hospital
Recruiting

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Completed

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Semaglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting

Characterization of Retinal Vascular Disease in Eyes With Mild to Moderate NPDR in Diabetes Type 2

Condition:   NPDR - Non Proliferative Diabetic Retinopathy
Intervention:   Diagnostic Test: Laboratory tests
Sponsors:   Association for Innovation and Biomedical Research on Light and Image;   Fundação para a Ciência e a Tecnologia
Active, not recruiting

Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination

Conditions:   Diabetic Nephropathy Type 2;   Microalbuminuria Due to Type 2 Diabetes Mellitus
Intervention:   Drug: Tritace (Ramipril 10 mg)
Sponsor:   Beni-Suef University
Recruiting

Specific Clinical Experience Investigation for Long-term Use of Bydureon.

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Empagliflozin
Sponsor:   Boehringer Ingelheim
Completed

Dynamically Tailored Behavioral Interventions in Diabetes

Condition:   Type 2 Diabetes
Intervention:   Behavioral: T2.coach
Sponsors:   Columbia University;   Clinical Directors Network;   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting

Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers

Conditions:   Obesity;   Type 2 Diabetes;   Gestational Diabetes
Intervention:  
Sponsors:   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Thrasher Research Fund;   American Diabetes Association
Recruiting

Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes

Conditions:   Obesity;   Diabetes
Interventions:   Other: Quercetin;   Other: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Dipeptidyl-peptidase 4 (DPP-4) inhibitors
Sponsor:   Boehringer Ingelheim
Recruiting

The Proportion of Patients With Non-diagnosed Diabetes Type 2

Condition:   Diabetes Mellitus, Type 2
Intervention:   Diagnostic Test: Diagnosis of diabetes (OGTT)
Sponsors:   Nutrition Institute, Slovenia;   National Institute of Public Health, Slovenia;   Ministry of Health of Republic of Slovenia;   Slovenian Research Agency
Not yet recruiting

T2DXcel Mobile Application

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: T2DXcel mobile application
Sponsor:   Montefiore Medical Center
Not yet recruiting

The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms

Conditions:   Atrial Fibrillation;   Type 2 Diabetes
Intervention:   Behavioral: High-intensity interval training + standard care
Sponsor:   Ottawa Heart Institute Research Corporation
Recruiting

Longitudinal Assessment of Bariatric Surgery Sub-Study

Conditions:   Obesity;   Diabetes Mellitus
Intervention:  
Sponsors:   Oregon Health and Science University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting

Linagliptin Add-on to Insulin Background Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin;   Drug: background therapy
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Completed

Renohemodynamic Effects of Combined empagliflOzin and LosARtan

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Kidney Disease
Interventions:   Drug: Empagliflozin 10 MG;   Drug: Losartan 50Mg Tab;   Other: Placebo
Sponsor:   VU University Medical Center
Not yet recruiting

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting

Urinary Vitamin C Loss in Diabetic Subjects

Conditions:   Diabetes Type 1;   Diabetes Type 2;   Healthy Volunteers
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Drug: Doxycycline;   Other: Placebo
Sponsors:   University of California, San Diego;   Ruth L. Kirschstein National Research Service Award;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Center for Research Resources (NCRR)
Completed

Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Effects of Diabetes Medications on Adrenal Function and Intestinal Microbiota

Condition:   Type 2 Diabetes
Interventions:   Drug: GLP-1 receptor agonist;   Drug: SGLT2 inhibitor
Sponsor:   University of Tartu
Recruiting

Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin aspart;   Drug: Novolog/Novorapid;   Drug: Insulin glargine (HOE901)
Sponsor:   Sanofi
Completed

Empaglifozin in Early Diabetic Kidney Disease

Conditions:   Diabetic Kidney Disease;   Diabetes Mellitus Type 2
Interventions:   Drug: Empagliflozin;   Other: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting

Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Placebo, Nicorandil, Glimepiride
Sponsor:   University of Copenhagen
Completed

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Dapagliflozin 5 mg;   Drug: Dapagliflozin 10 mg placebo to match;   Drug: Dapagliflozin 5 mg placebo to match;   Drug: Saxagliptin 5 mg;   Drug: Metformin
Sponsor:   AstraZeneca
Recruiting

Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients

Conditions:   Diabetes Type 2;   NAFLD
Interventions:   Other: Portfolio Diet;   Other: MUFA Diet
Sponsor:   Federico II University
Completed

Physical Activity and Participation

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Counseling;   Behavioral: Usual education
Sponsor:   VA Office of Research and Development
Completed

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Conditions:   Overweight;   Obesity
Interventions:   Drug: Tirzepatide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting

Explorative Assessment of Biomarkers in Overweight and Obese Subjects

Condition:   Prediabetes
Intervention:  
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Recruiting

Primary Care-Based Physical Activity for Diabetic Latinas

Conditions:   Diabetes;   Sedentary Lifestyle
Interventions:   Behavioral: Tailored Physical Activity Intervention;   Behavioral: Standard of Care
Sponsor:   University of California, San Diego
Terminated

Does Early Weight Loss Following Laparoscopic Sleeve Gastrectomy Affect Long-term Outcomes

Conditions:   Hypertension;   Diabetes Mellitus, Type 2;   Gastrostomy;   Morbid Obesity;   Weight Loss
Intervention:   Procedure: Laparoscopic sleeve gastrectomy
Sponsor:   Shaare Zedek Medical Center
Completed

Mapping Genes for Type 2 (Non-Insulin Dependent) Diabetes Mellitus

Conditions:   Genetic Variation;   Diabetes
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Conditions:   Diabetes;   Cardiovascular Disease
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Enrolling by invitation

PDD in Type 2 Diabetes w/wo Diastolic Dysfunction

Conditions:   Diabetes Mellitus, Type 2;   Diastolic Dysfunction
Interventions:   Drug: LCZ 696;   Drug: Placebos
Sponsor:   Mayo Clinic
Recruiting

Program of Healthy Lifestyle Promotion in Yaqui Indigenous in Sonora

Conditions:   Overweight;   Obesity
Intervention:   Behavioral: Healthy lifestyle promotion program
Sponsor:   Centro de Investigación en Alimentación y Desarrollo A.C.
Active, not recruiting

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Conditions:   Fatty Liver, Nonalcoholic;   NAFLD;   Nonalcoholic Fatty Liver Disease;   Nonalcoholic Steatohepatitis;   Digestive System Diseases
Interventions:   Drug: HTD1801;   Drug: Placebo
Sponsor:   HighTide Biopharma Pty Ltd
Active, not recruiting

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Condition:   Diabetes Mellitus, Type 2
Interventions:   Biological: Gan & Lee Insulin Glargine Injection;   Biological: Lantus®
Sponsor:   Gan and Lee Pharmaceuticals, USA
Active, not recruiting

Resistance Exercise on Postprandial Hyperglycemia in Patients With B-thalassemia Exhibiting Resistance to Insulin

Conditions:   Beta-Thalassemia;   Insulin Resistance;   PreDiabetes;   Diabetes Mellitus, Type 2
Intervention:   Other: Resistance exercise
Sponsor:   University of Thessaly
Completed

Bariatric Surgery and Male Reproductive Function

Conditions:   Obesity;   Diabetes Mellitus, Type 2;   Bariatric Surgery Candidate;   Roux en Y Gastric Bypass;   Sleeve Gastrectomy
Interventions:   Procedure: Sleeve gastrectomy;   Procedure: Roux-en-Y gastric bypass
Sponsor:   The Third Xiangya Hospital of Central South University
Not yet recruiting

Treatment of Hypertension During Sleep

Conditions:   Hypertension;   Hypertension, Systolic
Intervention:   Procedure: Treatment of elevated asleep SBP mean
Sponsor:   University of Vigo
Recruiting

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Conditions:   Healthy Volunteers Diabetes Mellitus, Type 2;   Healthy Volunteers Overweight;   Healthy Volunteers Obesity
Interventions:   Drug: Semaglutide (administered by DV3396 pen);   Drug: Semaglutide (administered by PDS290 pen)
Sponsor:   Novo Nordisk A/S
Completed

Evaluation of Glucose Control in Patients With Diabetes

Condition:   Glycemic Control
Interventions:   Other: Usual Diet Group;   Other: Group 1 Nutritional Shake;   Other: Group 2 Nutritional Shake
Sponsor:   Abbott Nutrition
Completed

PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin 10mg then Placebo Oral Tablet;   Drug: Placebo Oral Tablet then Dapagliflozin 10mg
Sponsors:   The University of Texas Health Science Center at San Antonio;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Single-anastomosis Duodeno Ileal Bypass (SADI) Versus Roux-en-Y Gastric Bypass

Condition:   Obesity, Morbid
Interventions:   Procedure: SADI-S;   Procedure: RYGB
Sponsor:   Hospices Civils de Lyon
Recruiting

Systemic Cross-talk Between Brain, Gut, and Peripheral Tissues in Glucose Homeostasis: Effects of Exercise Training

Conditions:   Obesity;   Insulin Resistance;   Type2 Diabetes;   Exercise Training
Intervention:   Behavioral: Exercise training
Sponsors:   University of Turku;   Helsinki University;   University of Eastern Finland;   Turku University Hospital;   Academy of Finland;   Finnish Cultural Foundation;   Diabetes Research Foundation, Finland;   Juho Vainio Foundation
Enrolling by invitation

Hospital Workplace Nutrition Study

Conditions:   Overweight;   Type2 Diabetes
Interventions:   Other: Plant-based diet;   Other: Control Diet
Sponsors:   Physicians Committee for Responsible Medicine;   Sibley Memorial Hospital
Not yet recruiting

Comparing Cardiovascular Risk Factors in Diabetic Smokers Using Cigarettes & Combustion-Free Nicotine Delivery Systems

Conditions:   Cardiovascular Risk Factor;   Diabetes Mellitus, Type 2
Interventions:   Other: TOBACCO CIGARETTES;   Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS)
Sponsors:   Eclat Srl.;   University of Catania
Not yet recruiting

Behavioral Chronotype: Impact on Sleep and Metabolism

Conditions:   Type2 Diabetes Mellitus;   Cardiovascular Diseases
Interventions:   Behavioral: Early Total Caloric Intake;   Behavioral: Late Total Caloric Intake;   Behavioral: Extended Overnight Fast
Sponsors:   University of Chicago;   National Institute on Aging (NIA);   Northwestern University
Recruiting

A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)

Conditions:   Non-Alcoholic Steatohepatitis (NASH);   Type2 Diabetes Mellitus
Intervention:   Biological: Oral Insulin
Sponsors:   Oramed, Ltd.;   Hadassah Medical Organization
Recruiting

Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients

Conditions:   End-Stage Kidney Disease;   Type 2 Diabetes Mellitus
Intervention:   Other: Glucose-containing compared to glucose-free hemodialysate
Sponsor:   Tampere University Hospital
Completed

Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy

Condition:   Diabetic Nephropathy
Interventions:   Drug: LMB763;   Other: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition:   Atherosclerosis
Interventions:   Drug: Canakinumab;   Drug: Placebo;   Drug: Standard of care
Sponsor:   Novartis Pharmaceuticals
Completed

Fat Cell Size in Insulin Resistance

Condition:   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Testing the Influence of Different Sugary Drink Warning Label Designs

Conditions:   Obesity;   Weight Gain;   Diabetes Type 2
Intervention:   Behavioral: Sugary drink warning labels
Sponsors:   University of Pennsylvania;   Drexel University;   New York University;   University of Connecticut;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting

The Effect of Different Starches of Boba Pearls and Sugar Substitutes Used in Milk Tea on Glycaemia, Insulinaemia and Appetite Control (Pearl Study)

Conditions:   Diabete Type 2;   Obese
Interventions:   Other: Starch 1;   Other: Starch 2;   Other: Starch 3;   Other: Starch 4;   Other: Sugar 1;   Other: Sugar 2
Sponsor:   Clinical Nutrition Research Centre, Singapore
Active, not recruiting

Reducing Diabetes Risk Factors in American Indian Children: Tribal Turning Point

Condition:   Overweight/Obesity
Interventions:   Behavioral: Active Living;   Other: Health and Safety
Sponsors:   University of Colorado, Denver;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Suspended

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Condition:   Obesity, Visceral
Interventions:   Drug: [U-13C3] glycerol;   Drug: Empagliflozin;   Drug: Placebo (for Empagliflozin)
Sponsors:   University of Texas Southwestern Medical Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Food and Education Effects on Diabetes Study

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Medically-tailored meal delivery and medical nutrition therapy
Sponsors:   Johns Hopkins University;   Moveable Feast;   Priority Partners MCO;   Leonard & Helen R. Stulman Charitable Foundation;   France-Merrick Foundation
Not yet recruiting

Effect of Self- and Family Management of Diabetic Foot Ulcers Programs on Health Outcomes

Conditions:   Diabete Mellitus;   Diabetic Foot
Interventions:   Behavioral: Self-and family management of diabetic foot ulcers programs;   Other: Usual care
Sponsor:   Universitas Muhammadiyah
Completed

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

Conditions:   C9orf72 Amyotrophic Lateral Sclerosis (ALS);   Frontotemporal Dementia
Intervention:   Drug: Metformin
Sponsor:   University of Florida
Recruiting

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Completed

A Study of LY900020 in Healthy Chinese Participants

Condition:   Healthy
Interventions:   Drug: LY900020;   Drug: Metformin XR;   Drug: Atorvastatin;   Drug: Valsartan
Sponsor:   Eli Lilly and Company
Active, not recruiting

Role of Fexofenadine in Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Fexofenadine Pill;   Drug: Placebo oral tablet
Sponsor:   Tanta University
Recruiting

Diabetes Self Management Education Programme in Thailand

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system
Sponsors:   London School of Hygiene and Tropical Medicine;   Medical Research Council;   Chiang Mai University
Not yet recruiting

Glycemic Monitoring in Cystic Fibrosis

Condition:   Cystic Fibrosis
Intervention:  
Sponsor:   University of Colorado, Denver
Active, not recruiting

Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease

Condition:   Parkinson's Disease
Intervention:   Drug: Exenatide extended release 2mg subcutaneous injection (Bydureon)
Sponsor:   University College, London
Not yet recruiting

Evaluation of Systemic Microvascular Endothelial Function in Metabolically Healthy Obesity

Conditions:   Obesity;   Dyslipidemias
Intervention:   Diagnostic Test: Evaluation of systemic skin microvascular endothelial function
Sponsor:   National Institute of Cardiology, Laranjeiras, Brazil
Recruiting

Weight Loss in Adults With Obesity Using a Combination of Low Energy Diet, Group Treatment and Intragastric Balloon

Conditions:   Obesity;   Weight Loss;   Non-Alcoholic Fatty Liver Disease
Interventions:   Dietary Supplement: Low energy diet using meal replacements;   Behavioral: CBT-based group treatment;   Device: Intragastric balloon
Sponsor:   Region Örebro County
Recruiting

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: Placebo;   Drug: Canagliflozin
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed

Ultrasound Measure of Gastric Volume in Diabetic and Non Diabetic Patients Before General Anesthesia

Condition:   Diabetes
Intervention:   Procedure: Ultrasonic measurement of antral area
Sponsor:   Hopital Foch
Completed

Peripheral Vascular REactivity and Muscular Oxygenation in Diabetes Mellitus

Conditions:   Diabetes Mellitus;   Vascular Complications;   Mitochondrial Diseases
Interventions:   Other: examination: blood pressure assessment;   Other: examination: Flow Mediated Dilatation (FMD)-test;   Other: examination: handgrip exercise test with Near infrared spectroscopy (NIRS)-monitoring;   Other: examination: measurement of glucose by a finger prick
Sponsors:   University Ghent;   University Hospital, Ghent
Not yet recruiting

The Effect of a Botanical Plant Extract on Gut Health, Immunity and Metabolic Disorders in Healthy Adults

Condition:   Healthy
Interventions:   Dietary Supplement: Low dose response efficacy of plant extracts;   Dietary Supplement: Middle dose response efficacy of plant extracts;   Dietary Supplement: High Dose response efficacy of plant extracts;   Dietary Supplement: Placebo
Sponsor:   University of Roehampton
Recruiting

Gastric Ultrasound of Diabetic and Non-Diabetic Patients Following Preoperative Fasting Instructions

Conditions:   Diabetes;   Diabetes Mellitus;   Diabetes Mellitus Type 1;   Diabetes Mellitus Type 2
Intervention:  
Sponsor:   University Health Network, Toronto
Recruiting

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Inflammation;   Insulin Resistance;   Noninsulin-dependent Diabetes Mellitus
Interventions:   Drug: Salsalate;   Drug: Placebo
Sponsors:   VA Office of Research and Development;   Joslin Diabetes Center
Completed

Balance Training in Diabetic Neuropathy

Condition:   Diabetic Neuropathy With Neurologic Complication
Interventions:   Other: Balance Training;   Other: General Exercises
Sponsor:   Dow University of Health Sciences
Recruiting

Use of CoG by Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus
Intervention:   Device: non-invasive tissue glucose prediction
Sponsors:   Sciema UG;   Cnoga Medical Ltd.
Completed

Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)

Conditions:   Atopic Dermatitis Eczema;   Atopic Dermatitis;   Eczema
Intervention:   Other: No intervention
Sponsors:   Momentum Data;   Pfizer;   Royal College of General Practitioners Research and Surveillance Centre
Active, not recruiting

Anesthesiology Control Tower

Condition:   Health Information Technology
Intervention:   Other: Anesthesiology Control Tower Feedback
Sponsors:   Washington University School of Medicine;   Agency for Healthcare Research and Quality (AHRQ)
Completed